Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2025 Jan 22;19(1):e0012826. doi: 10.1371/journal.pntd.0012826

A CRISPR-Cas12a-based universal rapid scrub typhus diagnostic method targeting 16S rRNA of Orientia tsutsugamushi

Bum Ju Park 1,2, Sang Taek Heo 3, Misun Kim 3, Jeong Rae Yoo 3, Eun Jin Bae 4, Su Yeon Kang 4, Sunghoon Park 5, Kyeo Re Han 5, Keun Hwa Lee 4, Jae Myun Lee 5, Hyeyoung Lee 2,6, Yoon-Jae Song 1,*
Editor: Yong Qi7
PMCID: PMC11790230  PMID: 39841710

Abstract

Scrub typhus is caused by Orientia tsutsugamushi infection and occurs frequently in an area called the Tsutsugamushi Triangle. Currently, there is no vaccine for O. tsutsugamushi, and its infection is treated with antibiotics such as doxycycline. Scrub typhus responds to effective treatment, and early treatment shortens the course of the disease, reduces mortality, and accelerates recovery. Therefore, it is important to rapidly diagnose O. tsutsugamushi infection to ensure successful outcomes. Here, we developed a CRISPR-Cas12a-based diagnostic method targeting the bacterial 16S rRNA to detect O. tsutsugamushi infection of all known genotypes. To reduce the possibility of contamination and increase field applicability, we designed the one-pot assay system in addition to conventional two-pot assay system. Using this method, we successfully detected up to 100 copies of in vitro transcribed O. tsutsugamushi 16S rRNA within 1 hour under isothermal conditions. In blood samples from patients confirmed to be infected with O. tsutsugamushi by nested PCR, the developed method exhibited a clinical sensitivity of 98% and high specificity. These data demonstrate that the presented method is applicable for the rapid and universal diagnosis of scrub typhus to facilitate timely and appropriate treatment.

Author summary

Early treatment with antibiotics can shorten the course of scrub typhus, reduce mortality, and accelerate recovery, making the rapid diagnosis of O. tsutsugamushi infection critically important. In this study, we developed a CRISPR-Cas12a-based rapid diagnostic method targeting the bacterial 16S rRNA to detect O. tsutsugamushi infection across all known genotypes. Using this method, we successfully detected as few as 100 copies of in vitro-transcribed O. tsutsugamushi 16S rRNA within 1 hour under isothermal conditions. In blood samples from patients confirmed to be infected with O. tsutsugamushi by nested PCR, the developed method demonstrated a clinical sensitivity of 98% and high specificity.

Introduction

Scrub typhus, caused by Orientia tsutsugamushi (O. tsutsugamushi), is a clinically significant vector-borne disease prevalent in the Asia-Pacific region, particularly within the Tsutsugamushi Triangle, which encompasses the Russian Far East, northern Australia, Afghanistan, and surrounding areas. Transmission occurs via the bite of infected Trombiculidae larvae, with clinical symptoms including fever, rash, and eschar at the bite site [1]. Severe cases may lead to complications such as hemophagocytic syndrome, meningitis, and multi-organ failure, with a mortality rate of approximately 6% without treatment [14]. Appropriate antibiotic therapy, including doxycycline, tetracycline, chloramphenicol, and azithromycin, reduces the mortality rate to 1.4% [1,2,5,6]. Despite its clinical significance, there is no effective vaccine for scrub typhus, making early and accurate diagnosis essential to reducing mortality and improving patient outcomes [7].

Currently, culture tests, antibody-detection tests, and nucleic acid-based tests (NATs) are used to diagnose O. tsutsugamushi [812]. Culture tests take several weeks to perform, have a sensitivity < 50%, and must be performed in a BSL-3 laboratory; thus, this strategy is more often used for bacterial isolation than for diagnosis [13]. The antibody-detection tests include those based on an indirect immunofluorescent-antibody test (IFA), passive hemagglutination assay (PHA), and enzyme-linked immunosorbent assay (ELISA) [8,10,14]. IFA can be used to compare the antibody titer between the acute and convalescent phases, and is widely used for diagnostic purposes due to its high sensitivity and specificity [8]. However, it requires expensive equipment, such as a fluorescence microscope, and cannot be scaled up for high-throughput diagnosis. Given this, IFA is most commonly used as a confirmation test in current practice [15]. ELISA is also used to compare antibody titers for diagnostic purposes; it is less costly than IFA while yielding a similar sensitivity [14]. However, both of these techniques require comparison of antibody values ​​in the acute and convalescent phases, and thus are not easily applicable for early diagnosis. PHA enables the user to visually detect the degree to which a patient’s serum aggregates with the antigen, but its sensitivity is low [10]. NATs using real-time or nested PCR represent the current standard for diagnosing O. tsutsugamushi infection; it and IFA are the most widely used methods for diagnosing scrub typhus [9,11]. However, real-time PCR may return false positives due to non-specific amplification and nested PCR, which avoids false positives, requires a secondary amplification step.

O. tsutsugamushi is an obligate, intracellular bacterium which belongs to family Rickettsiaceae and causes scrub typhus. Although the 16S rRNA sequence of O. tsutsugamushi matches those of Rickettsia species of the same family by about 90% [1618], major differences are seen in their cell wall components. The cell walls of Rickettsia comprise lipopolysaccharides, outer membrane B, and a 17-kDa lipoprotein, whereas those of O. tsutsugamushi lack these components and instead have a 56 kDa type-specific antigen (TSA56) that serves as a criterion for the diversity of O. tsutsugamushi strains [19, 20]. O. tsutsugamushi was initially classified into three prototypes (Karp, Kato, and Gilliam) based on antigenic similarity detected by complement-fixation (CF) analysis [21, 22]. Subsequently, the TSA56, which exhibits high antigenic variability, was used as a major antigenic determinant. Based on sequence analysis of the TSA56, researchers proposed nine distinct genotypes of O. tsutsugamushi in 2009, namely Karp, Kuroki, TA763, Gilliam, Kawasaki, Japanese Gilliam, Kato, Saitama, and Shimokoshi [23].

Recently, a field-applicable rapid molecular method for diagnosing pathogenic infection was developed based on the clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated proteins (Cas) immune system of bacteria [2426]. The CRISPR-Cas system uses an RNA-guided endonuclease to provide sequence-specific immunity against an invaded nucleic acid sequence (e.g., from a plasmid or bacteriophage). The RNA used for the RNA-guided endonuclease is called guide RNA (gRNA) or CRISPR RNA (crRNA) and is derived from the invaded nucleic acid sequence. The previously reported diagnostic method utilized a Cas12a protein comprising a gRNA complementary to the target DNA sequence plus a T nucleotide-rich protospacer-adjacent motif (PAM). Binding of Cas12a to a target DNA activated its trans-cleavage activity to cleave nearby single-strand DNA. Using Cas12a and isothermal amplification, Jenifer Doudna and colleagues developed a molecular diagnostics technology called DNA Endonuclease-TargEted CRISPR Trans Reporter (DETECTR) [24]. Various pathogens, including human papilloma viruses (HPV), severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), severe fever with thrombocytopenia syndrome virus (SFTSV), and human immunodeficiency virus (HIV) were detected using the DETECTR platform, and Cas12a-based pathogen diagnosis is currently utilized in the clinic [24,27,28].

In the present study, we designed a primer-gRNA set for the targeted detection of the 16S rRNAs of O. tsutsugamushi. The 16S rRNA sequence is commonly used for bacterial classification. Unlike other mRNA molecules, this rRNA resembles DNA in having a stable structure with many secondary structures, and thus is not easily degraded during its isolation from cells or use in experiments. Furthermore, whereas O. tsutsugamushi contains a single copy of a given DNA target [29], it may have hundreds to thousands of copies of an RNA target. The O. tsutsugamushi 16S rRNA is transcribed consistently enough to be used as a housekeeping gene in the microarray analysis [30]. For these reasons, we hypothesized that using the 16S rRNA gene as a detection target would yield high-level sensitivity for O. tsutsugamushi. Both antibody-detection tests and NATs for scrub typhus diagnosis rely on the TSA56. However, the high antigenic variability of TSA56 complicates these methods, resulting in inconsistent detection and reduced sensitivity [31]. Molecular diagnostics targeting the conserved 16S rRNA sequence address these limitations, enabling consistent and reliable detection across diverse O. tsutsugamushi genotypes. We designed primer-gRNA sets to detect nine genotypes of O. tsutsugamushi, and used them to develop a CRISPR-Cas12a-based diagnostic method for detecting O. tsutsugamushi, which we named O. tsutsugamushi DETECTR or OT DETECTR.

Materials and methods

Ethics statement

This study was approved by the Institutional Review Board (IRB) of Jeju National University Hospital (IRB no.2022-05-002). Written informed consent was obtained from all the participants.

Two-pot OT DETECTR

In our two-pot Cas12a-based diagnostic method, the isothermal amplification and Cas12a trans-cleavage steps were performed in different Eppendorf tubes (two-pot) at two different temperatures (Fig 1A). The bacterial DNA and RNA were amplified by recombinase polymerase amplification (RPA) and reverse transcription recombinase polymerase amplification (RT-RPA), respectively, using a TwistAmp Basic kit (TwistDx, Cambridge, UK). The utilized primer sets, designed to detect the OT1 and OT2 sequences (Table 1), were designed according to the provided protocol, with reference to the aligned 16S rRNA sequence for nine genotypes of O. tsutsugamushi (S1 Fig): Karp, Kuroki, TA763, Gilliam, Kawasaki, Japanese Gilliam, Kato, and Shimokoshi (GenBank accession numbers: NR_025860.1, D38626.1, NZ_OUNA00000000.1, D38622.1, D38625.1, AP008981.1, NZ_LS398550.1, D38627.1, respectively; NCBI). The Saitama strain was excluded because it was not published in NCBI. As described in the provided protocol, the RPA reaction mixture comprised 29.5 μL rehydration buffer, 2.4 μL forward and reverse primers (10 μM each), and 2.5 μL of 280 mM magnesium acetate, with samples and nuclease-free water added obtain a final volume of 50 μL. Each RPA reaction mixture was incubated at 39°C for 40 min. The RT-RPA reaction mixture comprised 29.5 μL rehydration buffer, 2.4 μL forward and reverse primers (10 μM each), 1 μL SuperScript IV Reverse Transcriptase (Invitrogen, Waltham, Massachusetts, USA), 1 μL RNase inhibitor (Enzynomics, Daejeon, Korea), and 2.5 μL of 280 mM magnesium acetate, with samples and nuclease-free water added to obtain a final volume of 50 μL. Each RT-RPA reaction mixture was incubated at 42°C for 40 min.

Fig 1. Schematic diagrams of OT DETECTRs.

Fig 1

(A) Conventional two-pot OT DETECTR. (B) One-pot OT DETECTR.

Table 1. RT-RPA primer and gRNA sequences.

Target gene Sequence PAM
RT-RPA primer OT1-F 16S rRNA GGCTTAACCCTGGAACTGCTTCTAAAACTG
OT1-R 16S rRNA CTTTCGCCACTGGTGTTCCTTCTAATATCT
OT2-F 16S rRNA GTGCTAGATATTGGGGGATTTTTCTTTCAG
OT2-R 16S rRNA TTGGTAAGGTTTTTCGCGGATCATCGAATT
gRNA OT1 16S rRNA TAGTGTAGAGGTAAAATTCT TTTC
OT2 16S rRNA GTAGCTAACGCATTAAGCAC TTTC

LbCas12a trans-cleavage assays were performed as previously described [24,27]. To design gRNA for detection the nine types of O. tsutsugamushi, the previously reported O. tsutsugamushi 16S rRNA sequences were obtained from NCBI and screened for shared subsequences. From this analysis, we designed and synthesized two gRNAs, OT1 and OT2 which corresponded to nucleotides 615–634 and 791–810, respectively (Bioneer, Daejeon, Korea) and were expected to specifically detect the O. tsutsugamushi 16S rRNA of all nine genotypes but not those of other bacterial genomes (Table 1). LbCas12a (New England Biolabs, Ipswich, Massachusetts, USA) and LbCas12a-specific gRNA were mixed with 1× NEBuffer 2.1 to final concentrations of 50 nM and 62.5 nM, respectively, and then mixed together and incubated at 37°C for 30 min to generate LbCas12a-gRNA complexes. For fluorescence assays, 2 μL of RT-RPA products, 80 μL of 1× NEBuffer 2.1, 18 μL of LbCas12a-gRNA complex and 2 μL of 10 μM FQ-labeled reporter (/56-FAM/TTATT/3IABkFQ/; Integrated DNA Technologies, Coralville, IA, USA) were dispensed directly to 96-well microplates, which were incubated at 37°C for 20 min. Fluorescence measurements were taken at the beginning and end of the incubation period using the Glomax Discover Microplate Reader (Promega, Madison, WI, USA) equipped with version 4.0.0 software (λex, 485 nm; λem, 535 nm). To simplify the visualization of results, we used a lateral flow assay (LFA). For the LFA, 2 μL of RT-RPA products, 40 μL of 1× NEBuffer 2.1, 36 μL of LbCas12a-gRNA complex and 2 μL of 10 μM lateral flow cleavage reporter (/56-FAM/TTATT/3Bio/; Integrated DNA Technologies) were combined in an Eppendorf tube and incubated at 37°C for 20 min. A Milenia HybriDetect 1 lateral flow strip (Milenia Biotec, Giesesen, Germany) was applied to the incubated sample according to the manufacturer’s instructions. The results were examined after 2 min and interpreted as previously described [27].

One-pot OT DETECTR

To prevent contamination and increase the field-applicability of OT DETECTR, we designed a one-pot OT DETECTR that is performed in a single tube. For this method, the LbCas12a-gRNA complex was generated by combining 3 μL of 1μM LbCas12a, 1 μL of 10 μM gRNA, 2 μL of 10 μM FQ-labeled reporter, and 54 μL of 1× NEBuffer 2.1 in an Eppendorf tube, which was then fitted with a 0.22 μm filter tube (SPL Life Sciences, Pocheon, Korea). The above-described RT-RPA mixture was loaded to the 0.22 μm-filter tube, and the assemblage was incubated at 42°C for 40 min. The LbCas12a-gRNA complex and RT-RPA product were then mixed via centrifugation (13,000 rpm, 1 min) and further incubated at 42°C for 20 min (Fig 1B). Fluorescence results were obtained at the start and end of incubation (λex, 485 nm; λem, 535 nm).

Bacteria

Bacterial cultures of Staphylococcus aureus (SA), Klebsiella pneumoniae (KP), Salmonella enteritidis (SE), and E. coli were grown overnight at 37°C in 5 mL LB broth, and bacterial RNA was extracted using a bacterial RNA extraction kit (Bioneer, Daejeon, Korea). SA, KP and SE were kindly provided by Dr. Young-Seo Park (Gachon University, Korea).

O. tsutsugamushi (Ikeda strain; National Culture Collection for Pathogens, NCCP) was inoculated to a monolayer of L929 cells. At 4 days post-infection, the cells were collected and homogenized with sterile glass beads using a TissueLyser II (Qiagen, Hilden, Germany). The homogenate was centrifuged at 500×g for 5 min, the supernatant was collected, and cell-free bacteria were collected by high-speed centrifugation at 6000×g for 30 min and resuspended in DMEM. The infectivity titer of the inoculum was determined using an immunofluorescence assay, and the infected cell-counting unit (ICU) was calculated as follows: ICU = (total number of cells used for infection) × (ratio of infected cells to counted cells) × (dilution fold of O. tsutsugamushi Ikeda inoculum) [32]. The O. tsutsugamushi genomic DNA and RNA were extracted using Qiagen DNeasy Blood & Tissue Kit and Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany), respectively. The O. tsutsugamushi genomic DNA and RNA were used for comparative testing of O. tsutsugamushi DNA molecules and RNA molecules content rates.

In vitro transcription of O. tsutsugamushi and Rickettsia spp. 16S rRNAs

The 16S rRNA was synthesized by an in vitro transcription (IVT) reaction and used to test the limit of detection (LoD) and specificity for each version of OT DETECTR. The 16S rRNA sequences of 8 strains O. tsutsugamushi: Karp, Kuroki, TA763, Gilliam, Kawasaki, Japanese Gilliam, Kato, and Shimokoshi (GenBank accession numbers: NR_025860.1, D38626.1, NZ_OUNA00000000.1, D38622.1, D38625.1, AP008981.1, NZ_LS398550.1, D38627.1, respectively; NCBI), were synthesized in plasmid form (Macrogen, Seoul, Korea) and PCR amplified using primers with T7 promoter sequences (Table 2). The primers and gRNA designed for O. tsutsugamushi detection showed similarity to regions in the 16S rRNA of Rickettsia spp., including species from the spotted fever and typhus groups (S1 Table). This region was identical across all 18 Rickettsia species analyzed, and the sequence was synthesized as plasmid DNA for experimental use. The 16S rRNA sequence was then amplified using primers with T7 promoter sequences (Table 2). For the IVT reaction, the mMESSAGE mMACHINE T7 Transcription kit (Invitrogen, Waltham, MA, USA) was applied according to the manufacturer’s instructions, with the above-described PCR products used as the template. The synthesized 16S rRNA was purified with a GeneJET RNA Cleanup and Concentration Micro Kit (Thermo Scientific, Waltham, MA, USA).

Table 2. PCR primers used for in vitro transcription.

Bacteria Primer Sequence
O. tsutsugamushi T7 OT-F’ TAATACGACTCACTATAGGGAGAAACGAACGCTGGCGG
T7 OT-R’ GCAGGTTCCCCTACGGCTACCTTGTTACGACTTTAC
Rickettsia spp. T7 RS-F’ TAATACGACTCACTATAGGGAGAGGCTTAACCTCGGAA
T7 RS-R’ CCTTCGCCACCGGTGTTCCTCCTAATATCTAAGAATTT

Preparation of O. tsutsugamushi clinical samples

All O. tsutsugamushi cases were confirmed using nested PCR, a method commonly employed for its diagnosis in Korea, at Jeju National University Hospital (Jeju, Korea). To confirm O. tsutsugamushi infection in clinical samples, bacterial DNA and RNA were extracted from whole blood using a QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany) and QIAamp RNA Blood Mini kit (Qiagen, Hilden, Germany), respectively. Nested PCR was performed as previously described [11] to detect the gene encoding the TSA56 of O. tsutsugamushi in extracted bacterial DNA, and OT DETECTR was performed to detect the 16S rRNA of O. tsutsugamushi in bacterial RNA.

Statistical analysis

Data are expressed as mean ± standard deviation (SD) of three independent experiments. The significance of differences between two means was determined with the Student’s t-test using GraphPad Prism 7 (GraphPad Software, Inc., Sandiego, CA. USA). P-values were determined by unpaired two-sided Student’s t-tests. P-values < 0.05 were considered statistically significant.

Results

Designing a CRISPR-Cas12a-based assay for O. tsutsugamushi

We herein designed a CRISPR-Cas12a-based diagnostic assay for rapid and accurate diagnosis of O. tsutsugamushi 16S rRNA and designated it OT DETECTR. The 16S rRNA of O. tsutsugamushi was selected as the target because it has a stable secondary structure and exists in more copies than a DNA target would. We screened previously reported sequences of O. tsutsugamushi to design RPA primer-gRNA sets that recognized the 16S rRNAs of all O. tsutsugamushi genotypes but not those of other organisms, and selected two sets, OT1 and OT2 (S1 Fig.). The O. tsutsugamushi 16S rRNA was extracted using a column-based extraction kit, amplified by isothermal amplification (RT-RPA), and detected by leveraging Cas12a trans-cleavage activity (Fig 1A), which was determined by either fluorescence assay or LFA. To prevent contamination and increase the field applicability of our method, we further developed a one-pot OT DETECTR in which all reactions are performed in a single tube at the same temperature (Fig 1B), as compared to the two-pot OT DETECTR.

Using nucleic acids extracted from O. tsutsugamushi, we found that our 16S rRNA-based diagnostic method was more sensitive for RNA than DNA (Fig 2). DNA and RNA were extracted from various infected-cell counting units (ICUs) of O. tsutsugamushi, and the sensitivity of OT DETECTR was compared using a detection versus non-detection approach. The OT1 set could detect O. tsutsugamushi DNA at a titer of 104 ICU per reaction and RNA at a titer of 103 ICU per reaction, indicating that RNA target detection was 10 times more sensitive than DNA target detection (Fig 2A). The OT2 set detected both DNA and RNA of O. tsutsugamushi at a titer of 104 ICU per reaction and thus showed the same sensitivity (Fig 2B). Based on these results, we used the OT1 primer-gRNA set in subsequent experiments.

Fig 2. Comparative analysis of the sensitivity of the OT DETECTRs to O. tsutsugamushi DNA and RNA.

Fig 2

Various ICUs (105 to 101) of O. tsutsugamushi were lysed with a column-based extraction kit, and nucleic acids (DNA and RNA) were amplified via RT-RPA with primer sets specific for the 16S rRNA gene. RT-RPA products were detected using two-pot OT DETECTR combined with a fluorescence assay. Shown are results obtained using gRNAs (A) OT1 and (B) OT2 (n = 6 replicates). RFU, relative fluorescence unit; NC, no template control; ICU, infected cell-counting unit.

Measuring of the limit of detection (LoD) for OT DETECTR

To determine the LoD of the assay, two-pot and one-pot OT DETECTR methods combined with a fluorescence assay were performed using varying copy numbers of in vitro transcribed O. tsutsugamushi 16S rRNA from the Karp strain. Both OT DETECTRs could detect as little as 100 RNA copies per reaction (Fig 3A and 3B). The one-pot OT DETECTR showed higher fluorescence values compared to the two-pot DETECTR: The fluorescence values of the one-pot OT DETECTR were 70% and 187% higher than those of the two-pot DETECTR for 103 and 102 RNA copies per reaction, respectively.

Fig 3. LoD analyses of OT DETECTRs.

Fig 3

(A, B) To determine the LoD of each OT DETECTR, different copy numbers (103 to 100) of IVT O. tsutsugamushi 16S rRNA were used as templates for the (A) two-pot and (B) one-pot OT DETECTR combined with a fluorescence assay. Values are presented as means ± s.d. (error bars) (n = 3 replicates; ** P < 0.01, * P < 0.05 between samples, two-sample t-test). RFU, relative fluorescence unit; NC, no template control.

Specificity analysis of OT DETECTR

To determine the specificity of OT DETECTR, it was tested on genomic RNA from O. tsutsugamushi, S. aureus, K. pneumoniae, S. enteritidis, and E. coli, as well as on in vitro transcribed 16S rRNA from Rickettsia spp. (Fig 4). The two-pot and one-pot OT DETECTRs combined with a fluorescence assay both yielded positive results with RNA of O. tsutsugamushi, but not with that of S. aureus, K. pneumoniae, S. enteritidis, E. coli or Rickettsia spp.. Thus, OT DETECTR specifically detected O. tsutsugamushi without cross-reacting with S. aureus, K. pneumoniae, S. enteritidis, E. coli or Rickettsia spp.. The OT DETECTR’s ability to detect various O. tsutsugamushi strains was further evaluated. Both two-pot and one-pot OT DETECTR successfully detected major strains, including Karp, Kuroki, TA763, Gilliam, Kawasaki, Japanese Gilliam, Kato, and Shimokoshi (S2 Fig).

Fig 4. Specificity analyses of OT DETECTRs.

Fig 4

To determine the specificities of OT DETECTRs, 100 ng of RNA from each bacterial species and 105 copies of RNA from Rickettsia spp. were amplified using RT-RPA. The Cas12a trans-cleavage activity assay was subsequently performed, and the results were analyzed through fluorescence measurements. Values are presented as means ± s.d. (error bars) (n = 3 replicates; ** P < 0.01, between samples, two-sample t-test). RFU, relative fluorescence unit; NC, no template control; SA, Staphylococcus aureus; KP, Klebsiella pneumoniae; SE, Salmonella enteritidis; RS, Rickettsia spp.; OT, Orientia tsutsugamushi.

Applicability of OT DETECTR to clinical samples

To evaluate the clinical applicability of the one-pot and two-pot OT DETECTRs, we compared the results obtained from samples of patients confirmed to be infected with O. tsutsugamushi by nested PCR, a commonly used confirmatory method for diagnosing scrub typhus in Korea. A total of 125 clinical samples were evaluated for O. tsutsugamushi infection via nested PCR (S3 Fig). Among them, 50 clinical samples were confirmed to be positive for O. tsutsugamushi infection and 75 were confirmed to be negative (S3 Fig). The two-pot DETECTR combined with fluorescence assay or LFA detected 49 of 50 O. tsutsugamushi infection-positive samples (the long exception was patient #27) (Fig 5A). Similarly, the one-pot DETECTR combined with a fluorescence assay also confirmed infection in all clinical samples positive for O. tsutsugamushi infection except for patient #27 (Fig 6A). Among clinical samples negative for O. tsutsugamushi, the two-pot and one-pot DETECTRs yielded the same results as the nested PCR (Figs 5B and 6B). The application of OT DETECTR to clinical samples and its concordance analysis with nested PCR are summarized in Tables 3 and 4, respectively. Patient demographic and clinical characteristics, including age, gender, immunosuppression status, Charlson Comorbidity Index (CCI), and days since illness onset, are detailed in S2 Table.

Fig 5. Clinical applicability analysis of two-pot OT DETECTR.

Fig 5

Two-pot OT DETECTR was performed on clinical samples from (A) 50 patients confirmed positive or (B) 75 patients confirmed negative for O. tsutsugamushi infection by nested PCR. RNA was extracted from whole blood, RT-RPA was performed, the Cas12a trans-cleavage activity assay was performed, and the results were determined by a fluorescence assay or LFA. Genomic RNA of O. tsutsugamushi (100 ng) was used as a positive control. Values are presented as means ± s.d. (error bars) (n = 3 replicates; *** P < 0.001, ** P < 0.01, * P < 0.05 between samples, two-sample t-test). RFU, relative fluorescence unit; C-line, control line; T-line, test line; NC, no template control; PC, positive control.

Fig 6. Clinical applicability analysis of one-pot OT DETECTR.

Fig 6

One-pot OT DETECTR combined with a fluorescence assay was performed on clinical samples from (A) 50 patients confirmed positive or (B) 75 patients confirmed negative for O. tsutsugamushi infection by nested PCR. Genomic RNA of O. tsutsugamushi (100 ng) was used as a positive control. Values are presented as means ± s.d. (error bars) (n = 3 replicates; *** P < 0.001, ** P < 0.01, * P < 0.05 between samples, two-sample t-test). RFU, relative fluorescence unit; NC, no template control; PC, positive control.

Table 3. Performance of OT DETECTR on clinical samples.

True positive False negative True negative False positive Sensitivity
(95% CI)
Specificity
(95% CI)
Two-pot
OT DETECTR
49 1 75 0 98%
(89.35%~99.5%)
100%
(95.2%~100%)
One-pot
OT DETECTR
49 1 75 0 98%
(89.35%~99.5%)
100%
(95.2%~100%)

Table 4. Concordance analysis between nested PCR and OT DETECTR for O. tsutsugamushi detection.

Detection Outcome Nested PCR positive Nested PCR negative Total Percentage (%)
Two-pot OT DETECTR positive 49 0 49 * PPA: 98%
Two-pot OT DETECTR negative 1 75 76 ** NPA: 100%
Total 50 75 125
One-pot OT DETECTR positive 49 0 49 * PPA: 98%
One-pot OT DETECTR negative 1 75 76 ** NPA: 100%
Total 50 75 125

*PPA: positive percent agreement

**NPA: Negative percent agreement

Discussion

In this study, we developed a CRISPR-Cas12a-based diagnostic method for O. tsutsugamushi (OT DETECTR). We targeted the 16S rRNA, which is present in more copies than DNA, offers a stable secondary, and was found to yield a detection sensitivity more than 10 times greater than that for DNA when targeted by OT DETECTR. This enables reliable detection even in environments with low pathogen concentrations. Our method detected all O. tsutsugamushi genotypes with known sequences and exhibited high specificity (100%). The analytical sensitivity of this diagnostic method was 102 RNA copies per reaction, which is approximately 10-fold lower than that of the nested PCR used in conventional diagnostic methods [33]. Although nested PCR amplifies trace amounts of target DNA using two rounds of PCR, it has the disadvantages of requiring additional reaction time and posing a higher risk of contamination. Compared to the long reaction time of 3 hours 45 minutes for nested-PCR, OT DETECTR utilizes isothermal amplification and completes within 1 hour, making it a more suitable diagnostic technology for scrub typhus, where rapid diagnosis is critical.

Meanwhile, in an analysis conducted with blood samples from patients, the OT DETECTR exhibited a clinical sensitivity of 98% (49/50), which was highly consistent with the sensitivity of the nested PCR analysis (98%). The single false-negative sample (positive clinical sample no. 27) had a low purity ratio of absorbance at 260 nm and 280 nm (0.5), compared to other samples with ratios of 1.6 or higher. This suggests that the assay’s performance may be affected by sample quality. Moreover, while nested PCR requires a thermocycler and a reaction time of 3 h 45 min, OT DETECTR can provide results within 1 hour and uses an isothermal reaction. The ability of OT DETECTR to diagnose O. tsutsugamushi infection with high sensitivity and specificity in such a short time without the need for specialized equipment supports its applicability for the rapid diagnosis of scrub typhus to facilitate timely and appropriate treatment.

Beyond comparisons with nested PCR, evaluating OT DETECTR against quantitative methods like qPCR could further enhance its clinical applicability. While qPCR provides quantitative data, such as bacterial load in copies/ml, OT DETECTR focuses on rapid, qualitative detection, offering distinct advantages in resource-limited settings. A direct comparison with qPCR could provide deeper insights into OT DETECTR’s analytical performance and clinical applicability, especially in contexts requiring quantitative measurements. Future studies will include such comparisons to comprehensively assess OT DETECTR’s strengths and limitations.

In the conventional DETECTR protocol, the isothermal nucleic acid amplification and trans-cleavage reaction are conducted in separate tubes at different temperatures. This opens the possibility of sample contamination and/or error during the transfer of reaction materials. To address these issues, we devised a one-pot OT DETECTR. We placed the trans-cleavage reaction mixture at the bottom of an Eppendorf tube, inserted a filter into the tube, and loaded the nucleic acid amplification reaction mixture (i.e., RPA reaction mixture) into the filter. At a single temperature, the amplification step took place on the filter, a brief centrifugation was used to move the amplified product to the bottom of tube, and then the trans-cleavage reaction took place at the bottom of the tube. The devised one-pot DETECTR showed no difference in specificity and sensitivity compared to the conventional two-pot DETECTR, and actually exhibited higher fluorescence values in measuring trans-cleavage activity. This suggests that a one-pot system could perform at least as well as the corresponding two-pot system while potentially preventing contamination and/or errors during the diagnostic process and thereby resolving issues of false negatives. Currently, Inogenix Inc. is ​​evaluating and developing an OT DETECTR-based O. tsutsugamushi diagnostic kit that offers these features. Further studies are warranted to use the diagnostic kit for additional clinical samples and to evaluate its performance in field-based testing.

For the OT DETECTR presented in this study to be used for point-of-care testing (POCT), several technological barriers need to be overcome. First, it must be easy to extract nucleic acids from the blood of suspected patients. To tackle the challenge of nucleic acid extraction in resource-limited settings, we plan to investigate simplified methods, such as heat-based extraction techniques. These approaches aim to streamline sample preparation and improve the test’s practicality in field conditions. Second, it should use a reaction temperature setting that can be achieved using a battery-based device or an air-activated hand warmer. Third, it should involve the sequential progression of isothermal nucleic acid amplification and trans-cleavage reaction using microfluidics or a nanoplatform. Finally, it should use LFA or a mobile device-based technique for measuring fluorescence. If these technologies are developed and integrated, it is expected that a CRISPR-Cas12a-based POCT can be developed for use in low- and middle-income countries (LMICs), as well as in rural and remote areas with fragile healthcare systems.

Recently, Bhardwaj et al. reported a conventional CRISPR-Cas12a-based detection method, combined with LFA, which could detect a single gene copy of the genomic DNA from O. tsutsugamushi Karp and Gilliam strains [34]. Since LFA has the drawback of displaying a positive band depending on reaction time [35], further studies are required to verify these findings using quantitative methods, such as fluorescence assays.

Several studies have reported that a CRISPR-Cas13a-based assay can detect RNA without nucleic acid amplification [36, 37]. Therefore, we also tested a CRISPR-Cas13a-based assay with OT1 gRNA on a subset of clinical samples confirmed positive for O. tsutsugamushi infection. However, we failed to obtain any results (S4 Fig). We further used the two gRNAs (OT1 and OT2) for a CRISPR-Cas13a-based assay because the sensitivity of the assay was reported to be enhanced by the use of multiple primers [37]. However, despite many attempts, we were unable to replicate the previously reported success with Cas13a (S4 Fig).

Supporting information

S1 Fig

Sequence alignment of the (A) RPA primers and (B) gRNAs used in this study, relative to the different genotypes of O. tsutsugamushi. Sequences of OT1-R and OT2-R are shown in the reverse-complement orientation.

(TIF)

pntd.0012826.s001.tif (276KB, tif)
S2 Fig. Detection of major O. tsutsugamushi strains.

The in vitro transcribed RNA fragments from the 16S rRNA sequences of major O. tsutsugamushi strains (Karp, Kuroki, TA763, Gilliam, Kawasaki, Japanese Gilliam, Kato, and Shimokoshi) were used to evalulate (A) Two-pot DETECTR and (B) One-pot DETECTR. Values are presented as means ± s.d. (error bars) (n = 3 replicates; *** P < 0.001, ** P < 0.01, * P < 0.05 between samples, two-sample t-test). RFU, relative fluorescence unit; NC, no template control.

(TIF)

pntd.0012826.s002.tif (70.2KB, tif)
S3 Fig. Nested PCR-based analysis of O. tsutsugamushi infection in clinical samples.

Nested PCR was performed to assess O. tsutsugamushi infection in 125 clinical samples from patients believed to be positive or negative for infection, and the product (483 bp) was visualized via gel electrophoresis. Of the total 125 samples, (A) 50 samples were confirmed positive for O. tsutsugamushi infection, and (B) 75 samples were confirmed negative for O. tsutsugamushi infection.

(TIF)

pntd.0012826.s003.tif (1.7MB, tif)
S4 Fig. Evaluating the applicability of LwCas13a-based detection using clinical samples from patients with confirmed O. tsutsugamushi infection.

Clinical samples from 10 patients with confirmed O. tsutsugamushi infection were analyzed using OT DETECTR with (A) Cas13a-OT1 gRNA or (B) multiple gRNAs (Cas13a-OT1 and Cas13a-OT2). Values are presented as means ± s.d. (error bars) (n = 3 replicates; * p < 0.05 between samples, two-sample t-test). RFU, relative fluorescence unit; NC, no template control; PC, Positive control (in vitro transcribed O. tsutsugamushi 16S rRNA)

(TIF)

pntd.0012826.s004.tif (54.2KB, tif)
S1 Table. 16S rRNAs of Rickettsia spp.

(DOCX)

pntd.0012826.s005.docx (19.7KB, docx)
S2 Table. Information on patients with positive O. tsutsugamushi infection.

(DOCX)

pntd.0012826.s006.docx (23.5KB, docx)
S1 Materials and Methods. Cas13a cleavage reaction.

(DOCX)

pntd.0012826.s007.docx (18.2KB, docx)

Data Availability

The manuscript provides patient demographics and clinical characteristics, such as age, gender, immunosuppression status, Charlson Comorbidity Index (CCI), and days since illness onset. Beyond this information, the disclosure of raw clinical data (including personal details) to third parties without prior consent from the data subjects is prohibited by law. For inquiries regarding the raw clinical data, please contact Jeju National University Hospital Institutional Review Board (irb1503@jejunuh.co.kr). The utilized primer sets, designed to detect the OT1 and OT2 sequences (Table 1), were designed according to the provided protocol, with reference to the aligned 16S rRNA sequence for nine genotypes of O. tsutsugamushi (S1 Fig): Karp, Kuroki, TA763, Gilliam, Kawasaki, Japanese Gilliam, Kato, and Shimokoshi (GenBank accession numbers: NR_025860.1, D38626.1, NZ_OUNA00000000.1, D38622.1, D38625.1, AP008981.1, NZ_LS398550.1, D38627.1, respectively; NCBI). The Saitama strain was excluded because it was not published in NCBI.

Funding Statement

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI22C0286). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Taylor AJ, Paris DH, Newton PN. A systematic review of mortality from untreated scrub typhus (Orientia tsutsugamushi). PLoS neglected tropical diseases. 2015;9(8):e0003971. doi: 10.1371/journal.pntd.0003971 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Li W, Huang L, Zhang W. Scrub typhus with multi-organ dysfunction syndrome and immune thrombocytopenia: a case report and review of the literature. Journal of Medical Case Reports. 2019;13(1):1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ono Y, Ikegami Y, Tasaki K, Abe M, Tase C. Case of scrub typhus complicated by severe disseminated intravascular coagulation and death. Emergency Medicine Australasia. 2012;24(5):577–80. doi: 10.1111/j.1742-6723.2012.01600.x [DOI] [PubMed] [Google Scholar]
  • 4.Sankhyan N, Saptharishi L, Sasidaran K, Kanga A, Singhi SC. Clinical profile of scrub typhus in children and its association with hemophagocytic lymphohistiocytosis. Indian pediatrics. 2014;51:651–3. doi: 10.1007/s13312-014-0470-4 [DOI] [PubMed] [Google Scholar]
  • 5.Kim Y-S, Lee HJ, Chang M, Son SK, Rhee YE, Shim SK. Scrub typhus during pregnancy and its treatment: a case series and review of the literature. The American journal of tropical medicine and hygiene. 2006;75(5):955–9. [PubMed] [Google Scholar]
  • 6.Phimda K, Hoontrakul S, Suttinont C, Chareonwat S, Losuwanaluk K, Chueasuwanchai S, et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrobial agents and chemotherapy. 2007;51(9):3259–63. doi: 10.1128/AAC.00508-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Walker DH, Mendell NL. A scrub typhus vaccine presents a challenging unmet need. npj Vaccines. 2023;8(1):11. doi: 10.1038/s41541-023-00605-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Blacksell SD, Bryant NJ, Paris DH, Doust JA, Sakoda Y, Day NP. Scrub typhus serologic testing with the indirect immunofluorescence method as a diagnostic gold standard: a lack of consensus leads to a lot of confusion. Clinical infectious diseases. 2007;44(3):391–401. doi: 10.1086/510585 [DOI] [PubMed] [Google Scholar]
  • 9.Jiang J, Chan T-C, Temenak JJ, Dasch GA, Ching W-M, Richards AL. Development of a quantitative real-time polymerase chain reaction assay specific for Orientia tsutsugamushi. American Journal of Tropical Medicine and Hygiene. 2004;70(4):351. [PubMed] [Google Scholar]
  • 10.Kim D, Lee Y-M, Back J-H, Yang T, Lee J, Song H-J, et al. A serosurvey of Orientia tsutsugamushi from patients with scrub typhus. Clinical Microbiology and Infection. 2010;16(5):447–51. doi: 10.1111/j.1469-0691.2009.02865.x [DOI] [PubMed] [Google Scholar]
  • 11.Lee Y-M, Kim D-M, Lee S-H, Jang M-S, Neupane GP. Phylogenetic analysis of the 56 kDa protein genes of Orientia tsutsugamushi in southwest area of Korea. The American journal of tropical medicine and hygiene. 2011;84(2):250. doi: 10.4269/ajtmh.2011.09-0601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Urakami H, Tsuruhara T, Tamura A. Penetration of Rickettsia tsutsugamushi into cultured mouse fibroblasts (L cells): an electron microscopic observation. Microbiology and immunology. 1983;27(3):251–63. doi: 10.1111/j.1348-0421.1983.tb03587.x [DOI] [PubMed] [Google Scholar]
  • 13.Fdr Gouriet, Fenollar F, Patrice J-Y, Drancourt M, Raoult D. Use of shell-vial cell culture assay for isolation of bacteria from clinical specimens: 13 years of experience. Journal of clinical microbiology. 2005;43(10):4993–5002. doi: 10.1128/JCM.43.10.4993-5002.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ha N-Y, Kim Y, Choi J-H, Choi M-S, Kim I-S, Kim Y-S, et al. Detection of antibodies against Orientia tsutsugamushi Sca proteins in scrub typhus patients and genetic variation of sca genes of different strains. Clinical and Vaccine Immunology. 2012;19(9):1442–51. doi: 10.1128/CVI.00285-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Luce-Fedrow A, Lehman ML, Kelly DJ, Mullins K, Maina AN, Stewart RL, et al. A review of scrub typhus (Orientia tsutsugamushi and related organisms): then, now, and tomorrow. Tropical medicine and infectious disease. 2018;3(1):8. doi: 10.3390/tropicalmed3010008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Moron CG, Popov VL, Feng H-M, Wear D, Walker DH. Identification of the target cells of Orientia tsutsugamushi in human cases of scrub typhus. Modern Pathology. 2001;14(8):752–9. doi: 10.1038/modpathol.3880385 [DOI] [PubMed] [Google Scholar]
  • 17.Ohashi N, Fukuhara M, Shimada M, Tamura A. Phylogenetic position of Rickettsia tsutsugamushi and the relationship among its antigenic variants by analyses of 16S rRNA gene sequences. FEMS microbiology letters. 1995;125(2–3):299–304. doi: 10.1111/j.1574-6968.1995.tb07372.x [DOI] [PubMed] [Google Scholar]
  • 18.Tamura A, Ohashi N, Urakami H, Miyamura S. Classification of Rickettsia tsutsugamushi in a new genus, Orientia gen. nov., as Orientia tsutsugamushi comb. nov. International Journal of Systematic and Evolutionary Microbiology. 1995;45(3):589–91. [DOI] [PubMed] [Google Scholar]
  • 19.Tamura A, Ohashi N, Urakami H, Takahashi K, Oyanagi M. Analysis of polypeptide composition and antigenic components of Rickettsia tsutsugamushi by polyacrylamide gel electrophoresis and immunoblotting. Infection and immunity. 1985;48(3):671–5. doi: 10.1128/iai.48.3.671-675.1985 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Stover C, Marana D, Carter J, Roe B, Mardis E, Oaks E. The 56-kilodalton major protein antigen of Rickettsia tsutsugamushi: molecular cloning and sequence analysis of the sta56 gene and precise identification of a strain-specific epitope. Infection and immunity. 1990;58(7):2076–84. doi: 10.1128/iai.58.7.2076-2084.1990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.SHISHIDO A. Strain variation of Rickettsia orientalis in the complement fixation test. Japanese Journal of Medical Science and Biology. 1964;17(2–3):59–72. doi: 10.7883/yoken1952.17.59 [DOI] [PubMed] [Google Scholar]
  • 22.Shishido A. Identification and serological classification of the causative agent of scrub typhus in Japan. Jpn J Sci Biol. 1962;15:308–21. [Google Scholar]
  • 23.Kelly DJ, Fuerst PA, Ching W-M, Richards AL. Scrub typhus: the geographic distribution of phenotypic and genotypic variants of Orientia tsutsugamushi. Clinical infectious diseases. 2009;48(Supplement_3):S203–S30. doi: 10.1086/596576 [DOI] [PubMed] [Google Scholar]
  • 24.Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018;360(6387):436–9. Epub 20180215. doi: 10.1126/science.aar6245 ; PubMed Central PMCID: PMC6628903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360(6387):439–44. Epub 20180215. doi: 10.1126/science.aaq0179 ; PubMed Central PMCID: PMC5961727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science. 2018;360(6387):444–8. doi: 10.1126/science.aas8836 ; PubMed Central PMCID: PMC6197056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38(7):870–4. Epub 20200416. doi: 10.1038/s41587-020-0513-4 ; PubMed Central PMCID: PMC9107629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Park BJ, Yoo JR, Heo ST, Kim M, Lee KH, Song YJ. A CRISPR-Cas12a-based diagnostic method for multiple genotypes of severe fever with thrombocytopenia syndrome virus. PLoS Negl Trop Dis. 2022;16(8):e0010666. Epub 20220802. doi: 10.1371/journal.pntd.0010666 ; PubMed Central PMCID: PMC9345333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Stoddard SF, Smith BJ, Hein R, Roller BR, Schmidt TM. rrn DB: improved tools for interpreting rRNA gene abundance in bacteria and archaea and a new foundation for future development. Nucleic acids research. 2015;43(D1):D593–D8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Cho BA, Cho NH, Min CK, Kim SY, Yang JS, Lee JR, et al. Global gene expression profile of Orientia tsutsugamushi. Proteomics. 2010;10(8):1699–715. doi: 10.1002/pmic.200900633 [DOI] [PubMed] [Google Scholar]
  • 31.Kim G, Ha N-Y, Min C-K, Kim H-I, Yen NTH, Lee K-H, et al. Diversification of Orientia tsutsugamushi genotypes by intragenic recombination and their potential expansion in endemic areas. PLoS neglected tropical diseases. 2017;11(3):e0005408. doi: 10.1371/journal.pntd.0005408 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Kim CG, Kim WK, Kim N, Pyung YJ, Park D-J, Lee J-C, et al. Intranasal immunization with nanoparticles containing an Orientia tsutsugamushi protein vaccine candidate and a polysorbitol transporter adjuvant enhances both humoral and cellular immune responses. Immune Network. 2023;23(6). doi: 10.4110/in.2023.23.e47 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kim D-M, Park G, Kim HS, Lee JY, Neupane GP, Graves S, et al. Comparison of conventional, nested, and real-time quantitative PCR for diagnosis of scrub typhus. Journal of clinical microbiology. 2011;49(2):607–12. doi: 10.1128/JCM.01216-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bhardwaj P, Nanaware NS, Behera SP, Kulkarni S, Deval H, Kumar R, et al. CRISPR/Cas12a-Based Detection Platform for Early and Rapid Diagnosis of Scrub Typhus. Biosensors (Basel). 2023;13(12). Epub 20231208. doi: 10.3390/bios13121021 ; PubMed Central PMCID: PMC10742217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Park BJ, Park MS, Lee JM, Song YJ. Specific Detection of Influenza A and B Viruses by CRISPR-Cas12a-Based Assay. Biosensors (Basel). 2021;11(3). Epub 20210319. doi: 10.3390/bios11030088 ; PubMed Central PMCID: PMC8003587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Fozouni P, Son S, Diaz de Leon Derby M, Knott GJ, Gray CN, D’Ambrosio MV, et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell. 2021;184(2):323–33 e9. Epub 20201204. doi: 10.1016/j.cell.2020.12.001 ; PubMed Central PMCID: PMC7834310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Shinoda H, Taguchi Y, Nakagawa R, Makino A, Okazaki S, Nakano M, et al. Amplification-free RNA detection with CRISPR–Cas13. Communications biology. 2021;4(1):476. doi: 10.1038/s42003-021-02001-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012826.r001

Decision Letter 0

Georgios Pappas, Yong Qi

24 Oct 2024

PNTD-D-24-01350A CRISPR-Cas12a-based universal rapid scrub typhus diagnostic method targeting 16s rRNA of Orientia tsutsugamushiPLOS Neglected Tropical Diseases Dear Dr. Song, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within 60 days Dec 23 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Yong QiAcademic EditorPLOS Neglected Tropical Diseases Georgios PappasSection EditorPLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

 Journal Requirements: Additional Editor Comments (if provided):   [Note: HTML markup is below. Please do not edit.] Reviewers' Comments: Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: While the objectives are generally clear, the study design and population description have limitations, particularly in terms of sample size and generalizability. The statistical analyses, though appropriate, could be more robustly presented, and no significant ethical concerns are evident.

The methods section of the manuscript has several deficiencies that could affect the robustness and generalizability of the results. First, the sample size of 125 clinical samples, while providing an initial proof of concept, is too small to offer strong statistical power or broad applicability across different populations and regions. The authors should consider increasing the sample size and including a more diverse set of samples, both geographically and in terms of disease severity, to better evaluate the test’s performance. Issues such as age, sex, days of illness, incredibly important in diagnostic circumstances and this information should be presented in the manuscript.

Additionally, the lack of field-based testing limits the study’s ability to address its objective of developing a point-of-care diagnostic tool. Testing under real-world conditions in resource-limited settings would provide critical insights into the feasibility and robustness of the test in practical applications.

Moreover, the statistical analysis, while appropriate in the use of Student’s t-test, lacks detailed presentation of critical values such as confidence intervals and p-values. The authors should enhance their statistical analysis by including these details and ensuring that significance is clearly marked in their results, especially within figures and tables. This would strengthen the reliability of the findings and allow for a clearer interpretation of the data.

Reviewer #2: (No Response)

Reviewer #3: The methods section is well-written, and the objectives are clear and appropriate. It would be helpful to specify the instrumentation and software used for fluorescence measurement in the assay. Additionally, could you elaborate on the rationale behind selecting specific strains like S. aureus and K. pneumoniae for specificity testing? Why were other Rickettsia species or other vector-borne pathogens not included?

Reviewer #4: 1.The term "universal diagnosis" should be validated with additional strains of Orientia spp. to ensure broader applicability. or it should demonstrate a board range of detection across known O. tsutsugamushi genotypes in the manuscript.

2.In the study design you mentioned “We designed primer-gRNA sets to detect nine genotypes of O. tsutsugamushi”

-Have you validated the detection efficacy for all nine genotypes in real samples?

3.For test validation, it would be beneficial to explain why Staphylococcus aureus (SA), Klebsiella pneumoniae (KP), Salmonella enteritidis (SE), and E. coli were used. Additionally, consider including more closely related bacteria from the Rickettsia group to strengthen the validation. If not please address why they were not include?

4.Do you plan to include a positive control or quality control for the each test runs? or provide explanation how will you validate each run.

5.Consider conducting a concordance analysis for positive predictive agreement (PPA) or negative productive agreement (NPA) with the reference assay.

6.In this study, the two assays used for validation are 'the OT DETECTR' targeting 16S rRNA and nested PCR targeting the 56 kDa gene. Please discuss this issue further, especially in light of the findings that there are 10-fold differences in the sensitivity.

7.Line 223: “All O. tsutsugamushi cases were laboratory confirmed at Jeju National University Hospital (Jeju, Korea)”

-Please provide more detail on the laboratory confirmation process. For clinical samples, scrub typhus infection is typically confirmed using a combination of antibody detection (such as serological assays; IFA) and antigen detection methods (e.g., PCR or Nested PCR) or bacterial isolation.

8.Line 227: Nested PCR was performed as previously described to detect the 56-kDa antigen of O. tsutsugamushi in extracted bacterial DNA

-Nested PCR not detect 56-kDa antigen, but detect the gene encoding the 56-kDa antigen, please clarify/correct.

9.Line 275: (B) OT2. (n = 6 replicates). No “.” After OT2

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: I would consider revising the statistical analysis. While the manuscript mentions the use of Student's t-test to evaluate differences between groups, the results lack thorough presentation of statistical significance directly within the figures and text. Important statistical details, such as confidence intervals and exact p-values, are not consistently provided, which weakens the impact of the findings. In some figures (e.g., Figures 2, 5, and 6), statistically significant differences are not marked, making it difficult for readers to quickly assess the reliability of the data.

What is the point of the sensitivity comparisons? The sensitivity comparison between DNA and RNA targets (e.g., in Figure 2) could be more clearly explained. While it is mentioned that RNA-based detection is more sensitive, the reasons for this improved sensitivity are not fully explored, and the implications for clinical applications are not discussed in sufficient detail. This omission leaves readers without a clear understanding of the practical significance of these findings.

The results for clinical samples, presented in Table 1, lack a breakdown of potential variability in patient presentations or sample quality. Issues such as days of illness and days of presentation are not considered – please provide this information in the revision of the manuscript. The manuscript does not explore whether the one false negative result was related to sample handling, disease stage, or other clinical factors, which limits the interpretation of the test’s real-world applicability.

The figures and tables in the manuscript could benefit from some enhancements to improve their clarity and accessibility. Specifically, Figure 2, which compares the sensitivity of the OT DETECTR to Orientia tsutsugamushi DNA and RNA, has small labels and data points that are difficult to read. Increasing the font size of axes labels and improving the color contrast between data points would enhance its legibility. Similarly, Figures 5 and 6, which present the clinical applicability of the two-pot and one-pot DETECTR assays, could be improved by adding annotations to indicate statistically significant differences directly on the graphs, making the results more immediately clear.

Reviewer #2: (No Response)

Reviewer #3: Patient #27 Analysis: Could you expand on the potential reasons for missing one patient (Patient #27)? Was there something unique about this case, such as a low bacterial load, that could impact the sensitivity of the assay?

Reviewer #4: 1. In the plots, for Y axis labeled “Fluorescence” please specify the units of detection.

2.In the plots, for X axis suggest RNA copies/reaction

3.Do you have information on the O. tsutsugamushi genotypes in confirmed scrub typhus cases? Do you have a plan to perform genotyping on these samples?

4. Have you compared this newly developed assay with quantitative detection methods (such as qPCR assay in unit of copies/ml)? If not, please consider discussing how this comparison could enhance its applicability in clinical cases.

5.Have you statistically compare the fluorescent intensity obtained from two-Pot versus one-Pot approach?

6.Could you provide details on demographic background and/or clinical sings of the scrub typhus confirmed cases used in the study?

7.Line 314: “nested PCR” is a gold-standard test for diagnosing scrub typhus.

-Do you have any reference for the use of nested PCR as a gold standard for diagnosing scrub typhus

8.Line 348: Italic for O. tsutsugamushi

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The discussion and general conclusion in the manuscript present a promising outlook on the CRISPR-Cas12a-based diagnostic tool for scrub typhus, but the limitations are not sufficiently detailed or critically examined. While the authors emphasize the potential for rapid detection and field applicability, they do not adequately address key challenges such as the test's reliance on RNA extraction, which is difficult to manage in low-resource settings. Additionally, the limitations of the small sample size and lack of field testing are underplayed, which could affect the generalizability of the findings to real-world conditions.

Furthermore, while the discussion briefly acknowledges the need for improved nucleic acid extraction and portability, the authors should have provided a more detailed exploration of how these technological barriers might impact the test's practicality in resource-limited settings. The conclusion, though optimistic, could be more balanced by discussing these limitations in greater depth and suggesting clear pathways for overcoming them, such as developing more robust, simplified sample processing methods or conducting larger field-based trials. Addressing these gaps would make the conclusion more grounded and credible.

Reviewer #2: (No Response)

Reviewer #3: The Discussion does a great job summarizing the study’s key findings, comparing OT DETECTR to existing methods, and outlining future directions for diagnostic development. However, it would be beneficial to address the limitations of OT DETECTR in this section.

Reviewer #4: 1.Using the phase “Data not shown” can reduce transparency of the discussion suggest to avoid data not shown statement in the manuscript.

2.Please consider discussing the cost evaluation of the CRISPR-Cas12a-based POCT in comparison to the currently used diagnostic processes in hospitals

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: While the manuscript is generally well-written, focusing on improving sentence clarity, streamlining some repetitive sections, and ensuring consistent formatting will improve its editorial quality. Proofreading for minor grammatical issues and enhancing the flow in certain areas will make it more reader-friendly.

It is unclear why the tables are clearly out of order - please re-order them so they read sequentially.

Please provide page numbers in the next revision.

Reviewer #2: (No Response)

Reviewer #3: 1.Line 48-49: Change "kDA" to "kDa."

Reviewer #4: Minor revision

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: While the CRISPR-Cas12a-based OT DETECTR method shows potential in a controlled laboratory environment, its application in real-world clinical and field settings faces several challenges. These include lower sensitivity compared to nested PCR, technical difficulties related to RNA extraction and handling, and the need for further validation in diverse clinical samples. To be viable as a widely adopted diagnostic tool for scrub typhus, these issues must be addressed, particularly to ensure its reliability in resource-limited environments where the disease is prevalent.

Reviewer #2: The manuscript presents a CRISPR-Cas12a-based diagnostic method for detecting Orientia tsutsugamushi, the causative agent of scrub typhus. The work is interesting and provides a valuable tool for rapid diagnosis.

Major Comments:

Logical Structure of the Introduction: The introduction lacks a clear flow of ideas. It directly delves into the biological details of O. tsutsugamushi without first establishing the background and the need for rapid diagnosis. I recommend reorganizing the introduction to first address the clinical significance of scrub typhus and the challenges posed by current diagnostic methods. Then, introduce the biological characteristics of the pathogen and explain why 16S rRNA was chosen as the detection target. The current discussion of antigen variability does not provide sufficient justification for the research focus of this work.

Overemphasis on Historical Background: The historical context of scrub typhus occupies a significant portion of the introduction, without directly contributing to the study’s objectives. I suggest simplifying or removing much of the historical background to better maintain focus on the diagnostic challenges and the novel aspects of this study.

Specificity Testing: The specificity validation in the manuscript is not comprehensive, as no tests are included against pathogens closely related to O. tsutsugamushi. To strengthen the reliability of the specificity data, I recommend including additional tests with related bacterial species. This would support the claim of high specificity and reduce potential concerns about cross-reactivity.

Reviewer #3: The authors have developed a CRISPR-Cas12a-based diagnostic method to detect multiple genotypes of O. tsutsugamushi by targeting the bacterial 16S rRNA. This method has been widely utilized for pathogen diagnosis, particularly due to its low cost, minimal instrument requirements, and reduced need for technical expertise. The OT DETECTR assay will be particularly valuable in field and low-resource laboratory settings, as it demonstrates high sensitivity and specificity.

The authors provide a thorough and clear background on Orientia tsutsugamushi. However, it would be beneficial to briefly elaborate on how antigenic variability impacts diagnosis and why this diversity complicates traditional diagnostic methods. This addition could strengthen the rationale for the use of molecular diagnostics in this context.

Reviewer #4: This manuscript is overall well-written and presents a promising new method that could be a valuable tool for scrub typhus diagnostics. However, there are areas that could benefit from improvement as mentioned above.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Piyanate Sunyakumthorn

Reviewer #4: No

 [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions. Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012826.r003

Decision Letter 1

Georgios Pappas, Yong Qi

6 Jan 2025

Dear Dr. Song,

We are pleased to inform you that your manuscript 'A CRISPR-Cas12a-based universal rapid scrub typhus diagnostic method targeting 16s rRNA of Orientia tsutsugamushi' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Yong Qi

Academic Editor

PLOS Neglected Tropical Diseases

Georgios Pappas

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

***********************************************************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #4: It's great to include the additional assay validation for Rickettsia spp. organisms.

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #4: All my comments have been adequately addressed.

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #4: All my comments have been adequately addressed.

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #4: Accept the revised version with no further comments.

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #4: The revised version has been further refined and thoroughly addresses all of my feedback.

I have no further comments.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #4: No

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012826.r004

Acceptance letter

Georgios Pappas, Yong Qi

17 Jan 2025

Dear Dr. Song,

We are delighted to inform you that your manuscript, "A CRISPR-Cas12a-based universal rapid scrub typhus diagnostic method targeting 16S rRNA of Orientia tsutsugamushi," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig

    Sequence alignment of the (A) RPA primers and (B) gRNAs used in this study, relative to the different genotypes of O. tsutsugamushi. Sequences of OT1-R and OT2-R are shown in the reverse-complement orientation.

    (TIF)

    pntd.0012826.s001.tif (276KB, tif)
    S2 Fig. Detection of major O. tsutsugamushi strains.

    The in vitro transcribed RNA fragments from the 16S rRNA sequences of major O. tsutsugamushi strains (Karp, Kuroki, TA763, Gilliam, Kawasaki, Japanese Gilliam, Kato, and Shimokoshi) were used to evalulate (A) Two-pot DETECTR and (B) One-pot DETECTR. Values are presented as means ± s.d. (error bars) (n = 3 replicates; *** P < 0.001, ** P < 0.01, * P < 0.05 between samples, two-sample t-test). RFU, relative fluorescence unit; NC, no template control.

    (TIF)

    pntd.0012826.s002.tif (70.2KB, tif)
    S3 Fig. Nested PCR-based analysis of O. tsutsugamushi infection in clinical samples.

    Nested PCR was performed to assess O. tsutsugamushi infection in 125 clinical samples from patients believed to be positive or negative for infection, and the product (483 bp) was visualized via gel electrophoresis. Of the total 125 samples, (A) 50 samples were confirmed positive for O. tsutsugamushi infection, and (B) 75 samples were confirmed negative for O. tsutsugamushi infection.

    (TIF)

    pntd.0012826.s003.tif (1.7MB, tif)
    S4 Fig. Evaluating the applicability of LwCas13a-based detection using clinical samples from patients with confirmed O. tsutsugamushi infection.

    Clinical samples from 10 patients with confirmed O. tsutsugamushi infection were analyzed using OT DETECTR with (A) Cas13a-OT1 gRNA or (B) multiple gRNAs (Cas13a-OT1 and Cas13a-OT2). Values are presented as means ± s.d. (error bars) (n = 3 replicates; * p < 0.05 between samples, two-sample t-test). RFU, relative fluorescence unit; NC, no template control; PC, Positive control (in vitro transcribed O. tsutsugamushi 16S rRNA)

    (TIF)

    pntd.0012826.s004.tif (54.2KB, tif)
    S1 Table. 16S rRNAs of Rickettsia spp.

    (DOCX)

    pntd.0012826.s005.docx (19.7KB, docx)
    S2 Table. Information on patients with positive O. tsutsugamushi infection.

    (DOCX)

    pntd.0012826.s006.docx (23.5KB, docx)
    S1 Materials and Methods. Cas13a cleavage reaction.

    (DOCX)

    pntd.0012826.s007.docx (18.2KB, docx)
    Attachment

    Submitted filename: Response to Revierwers.pdf

    pntd.0012826.s008.pdf (423.8KB, pdf)

    Data Availability Statement

    The manuscript provides patient demographics and clinical characteristics, such as age, gender, immunosuppression status, Charlson Comorbidity Index (CCI), and days since illness onset. Beyond this information, the disclosure of raw clinical data (including personal details) to third parties without prior consent from the data subjects is prohibited by law. For inquiries regarding the raw clinical data, please contact Jeju National University Hospital Institutional Review Board (irb1503@jejunuh.co.kr). The utilized primer sets, designed to detect the OT1 and OT2 sequences (Table 1), were designed according to the provided protocol, with reference to the aligned 16S rRNA sequence for nine genotypes of O. tsutsugamushi (S1 Fig): Karp, Kuroki, TA763, Gilliam, Kawasaki, Japanese Gilliam, Kato, and Shimokoshi (GenBank accession numbers: NR_025860.1, D38626.1, NZ_OUNA00000000.1, D38622.1, D38625.1, AP008981.1, NZ_LS398550.1, D38627.1, respectively; NCBI). The Saitama strain was excluded because it was not published in NCBI.


    Articles from PLOS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES